Withings BPM Pro 2 receives FDA clearance and CES recognition
Withings has announced FDA clearance for its BPM Pro 2, a next-generation blood pressure monitor that combines cellular connectivity with advanced features for remote patient monitoring. The device was recently named a CES 2025 Innovation Awards Honoree. The news follows the company’s recent $22.5 million investment in partnership with the French government for Project DEEP.
Refining blood pressure monitoring with FDA approval
Withings says the FDA clearance came through over the past weekend. It affirms the BPM Pro 2’s ability to measure blood pressure and pulse rate accurately.
The device supports the growing trend in healthcare toward remote monitoring solutions. These solutions aim to reduce pressure on healthcare systems and promote more proactive health management.
Withings BPM Pro 2 has an engaging, colour-screen interface which provides real-time feedback, educating users on how to take proper measurements and reducing the risk of inaccuracies. This addresses a key challenge in remote monitoring—ensuring reliable data collection from patients at home.
The device’s Retake Measure function is another thoughtful addition. If a reading falls outside pre-set thresholds, the BPM Pro 2 prompts patients to take another measurement. This helps ensure that only accurate data reaches healthcare providers, reducing the need for follow-up calls and avoiding unnecessary clinical interventions.
Streamlined workflows and patient engagement
But the BPM Pro 2 doesn’t just collect data—it also enriches it with context through its Patient Insights feature. This function allows care teams to gather additional details, such as symptoms or medication adherence, via customized prompts displayed on the device itself. This provides a more holistic view of the patient’s health without requiring extra effort from busy medical staff.
By automating tasks like symptom tracking and reminders, the BPM Pro 2 is designed to integrate into existing clinical workflows, allowing care teams to focus on patients with the most urgent needs. Its cellular connectivity further enhances usability, enabling instant data transmission to healthcare platforms, even in areas with limited network coverage. Backup options for WiFi and Bluetooth ensure no patient is excluded.
A broader push toward preventive healthcare
The FDA announcement is part of a larger narrative for Withings, which is making significant strides in promoting preventive care. Through its $22.5 million participation with the French government’s Project DEEP initiative, the company aims to help transform healthcare systems by equipping providers with tools that detect health issues earlier and reduce the strain on hospitals and clinics. The BPM Pro 2 exemplifies this mission, offering features that reduce clinical workloads.
CES 2025 is just around the corner. And Withings will be there showcasing its range of health products. In fact, BPM Pro 2 has snagged the CES 2025 Innovation Awards Honoree in the Digital Health category. The device was praised for its ability to combine clinical-grade measurements with user-friendly design, ensuring accessibility for patients across demographics.
The Withings BPM Pro 2 is now available for health professionals and care teams. A future update, pending FDA clearance, is set to bring 1-lead ECG functionality for detecting atrial fibrillation in 2025.
Like this article? Subscribe to our monthly newsletter and never miss out!
